Platelet rich plasma combined with subcision is a helpful therapeutic option for atrophic post-acne scarring

2021 ◽  
Vol 0 (0) ◽  
pp. 0-0
Author(s):  
walaa el shaarawy ◽  
Eman Salah eldin ◽  
Amany Nassar
Keyword(s):  
Platelet Rich Plasma ◽  
Therapeutic Option ◽  
Acne Scarring

scholarly journals TO EVALUATE THE EFFICACY AND SAFETY OF PLATELET RICH PLASMA (PRP) IN THE TREATMENT OF ACNE SCARRING IN DIFFERENT SKIN PHOTOTYPES

2019 ◽  
Vol 3 (5) ◽  
Author(s):  
Manish Kumar Meena ◽  
Deepika Meena ◽  
Dilip Kachhawa ◽  
R D Mehta
Keyword(s):  
Wound Healing ◽  
Platelet Rich Plasma ◽  
Therapeutic Option ◽  
Treatment Session ◽  
Efficacy And Safety ◽  
Medical College ◽  
Control Side ◽  
Acne Scarring ◽  
Comparative Prospective Study ◽  
Split Face

Background: Post acne scarring is a consequence of abnormal resolution or wound healing following the damage that occurs in the sebaceous follicle during acne inflammation Methods: Interventional split face comparative prospective study was conduct at Department of Dermatology, Venereology and Leprology, S N Medical College and Attached Hospitals, Jodhpur. Results: After one month of 3rd treatment session, 84% patients stated that they were satisfied or very satisfied on the platelet-rich plasma side, while 7% patients stated this about the normal saline side (P = 0.18).The platelet-rich plasma side was found to have a better response than the control side and participants were more satisfied with the platelet-rich plasma side than the control side. Conclusion: In conclusion, PRP alone provides better overall clinical improvement. We suggest that PRP should be considered as a monotherapy therapeutic option in the management of acne scars. Keywords: PRP, Scar, Acne

Concentrations of Blood Components in Commercial Platelet-Rich Plasma Separation Systems: A Review of the Literature

2018 ◽  
Vol 47 (2) ◽  
pp. 479-487 ◽  
Author(s):  
Bart W. Oudelaar ◽  
Joost C. Peerbooms ◽  
Rianne Huis in ‘t Veld ◽  
Anne J.H. Vochteloo
Keyword(s):  
Growth Factors ◽  
Growth Factor ◽  
Transforming Growth Factor ◽  
Platelet Rich Plasma ◽  
Therapeutic Option ◽  
Transforming Growth Factor Β1 ◽  
Future Research ◽  
Cochrane Central Register ◽  
Blood Components ◽  
Separation Systems

Background: Platelet-rich plasma (PRP) has proven to be a very safe therapeutic option in the treatment of tendon, muscle, bone, and cartilage injuries. Currently, several commercial separation systems are available for the preparation of PRP. The concentrations of blood components in PRP among these separation systems vary substantially. Purpose: To systematically review and evaluate the differences between the concentrations of blood components in PRP produced by various PRP separation systems. Study Design: Systematic review. Methods: MEDLINE/PubMed, the Cochrane Central Register of Controlled Trials (CENTRAL), and EMBASE were searched for studies that compared the concentrations of blood components and growth factors in PRP between various separation systems and studies that reported on the concentrations of blood components and growth factors of single separation systems. The primary outcomes were platelet count, leukocyte count, and concentration of growth factors (eg, platelet-derived growth factor–AB [PDGF-AB], transforming growth factor–β1 [TGF-β1], and vascular endothelial growth factor [VEGF]). Furthermore, the preparation protocols and prices of the systems were compared. Results: There were 1079 studies found, of which 19 studies were selected for inclusion in this review. The concentrations of platelets and leukocytes in PRP differed largely between, and to a lesser extent within, the studied PRP separation systems. Additionally, large differences both between and within the studied PRP separation systems were found for all the growth factors. Furthermore, preparation protocols and prices varied widely between systems. Conclusion: There is a large heterogeneity between PRP separation systems regarding concentrations of platelets, leukocytes, and growth factors in PRP. The choice for the most appropriate type of PRP should be based on the specific clinical field of application. As the ideal concentrations of blood components and growth factors for the specific fields of application are yet to be determined for most of the fields, future research should focus on which type of PRP is most suitable for the specific field.

scholarly journals Quality comparison between two different types of platelet-rich plasma for knee osteoarthritis

2020 ◽  
Vol 8 ◽  
pp. 3
Author(s):  
Takanori Wakayama ◽  
Yoshitomo Saita ◽  
Yohei Kobayashi ◽  
Hirofumi Nishio ◽  
Sayuri Uchino ◽  
...  
Keyword(s):  
Observational Study ◽  
Knee Osteoarthritis ◽  
Platelet Rich Plasma ◽  
Therapeutic Option ◽  
Interleukin 1 ◽  
Retrospective Observational Study ◽  
Health Concern ◽  
Preparation Methods ◽  
Different Types ◽  
Soluble Tnf Receptor

Introduction: Knee osteoarthritis (KOA), the most common form of osteoarthritis (OA) is a considerable health concern worldwide. Platelet-rich plasma (PRP) is a common therapeutic option for KOA. Different types of PRPs have varying efficacies. However, a comparative analysis of the qualities of these PRPs is lacking. Methods: Two types of PRPs, including autologous protein solution (APS), and leukocyte-poor PRP (LP-PRP) along with whole blood (WB) and platelet-poor plasma (PPP) were characterized for platelet content, leukocyte content, and composition in 10 healthy volunteers (HV) (the controlled laboratory study) and 16 KOA patients (a retrospective observational study). Additionally, the levels of the platelet-derived growth factor (PDGF)-BB, and different cytokines were estimated in HV. Results: In HV, the concentrations of platelets and leukocytes, levels of different cytokines, including interleukin 1 receptor antagonist (IL-1Ra), soluble TNF receptor type II (sTNF-RII), and IL-1β, and the ratio of IL-1Ra/IL-1β were significantly higher in APS, whereas the PDGF-BB was higher in LP-PRP than APS. In KOA patients, a higher concentration of platelets was observed in LP-PRP, and a higher concentration of leukocytes was observed in APS than LP-PRP. Following the PAW classification system, LP-PRP was classified as P2-B type in HV (51.3 × 104/μl) and KOA (53.4 × 104/μl), whereas APS was classified as P3-A type in HV (110.1 × 104/μl) and P2-A type in KOA (29.0 × 104/μl). In a retrospective observational study, the KOA patients who underwent APS injection had a higher incidence of arthralgia, and this arthralgia lasted for a longer time than LP-PRP injection in the same individual. Discussion: The quality of the two PRPs differed distinctively depending on their preparation methods, which might affect their clinical efficacies and adverse events. Therefore, the characterization of these parameters should be prioritized while choosing PRP.

scholarly journals First Approach to the Management of Orthopedic Injuries of the Hindfoot

2021 ◽  
Vol 3 (4) ◽  
pp. 01-03
Author(s):  
Claribel Pazos
Keyword(s):  
Soft Tissue ◽  
Platelet Rich Plasma ◽  
Therapeutic Option ◽  
Clinical Problem ◽  
Regenerative Therapy ◽  
Orthopedic Injuries ◽  
A New Technique ◽  
Methods Of Treatment ◽  
Common Clinical Problem ◽  
Anatomical Area

Hindfoot pain is a common clinical problem that can be due to multiple alterations, it can appear due to bone or soft tissue causes, it is established in a small anatomical area. There are different methods of treatment for these conditions, ranging from simple guidelines in lifestyle to surgery. In this work, patients are divided into four groups with different treatment methods, each group was assigned a different therapeutic option, which will increase its degree of invasion as the number of the group increases. Infiltration with platelet-rich plasma (PRP) is a new technique of cell regenerative therapy and was applied in one of the groups, taking advantage of the regenerative, healing and anti-inflammatory properties of the mentioned therapy.

scholarly journals Autologous Platelet Rich Plasma-A Biological Therapeutic Option for Retrocalcaneal Bursitis and its Associations

2019 ◽  
Vol 01 (01) ◽  
Author(s):  
Madhan Jeyaraman ◽  
Vishalkumar S Patel ◽  
Hardik J Dhamshania ◽  
Naveen Jeyaraman ◽  
Preethi Selvaraj
Keyword(s):  
Platelet Rich Plasma ◽  
Therapeutic Option ◽  
Retrocalcaneal Bursitis ◽  
Autologous Platelet Rich Plasma ◽  
Autologous Platelet

The Efficacy of Platelet-Rich Plasma in the Field of Hair Restoration and Facial Aesthetics—A Systematic Review and Meta-analysis

2019 ◽  
Vol 23 (2) ◽  
pp. 185-203 ◽  
Author(s):  
Aditya K. Gupta ◽  
Sarah G. Versteeg ◽  
Jeffrey Rapaport ◽  
Amelia K. Hausauer ◽  
Neil H. Shear ◽  
...  
Keyword(s):  
Platelet Rich Plasma ◽  
Meta Analysis ◽  
Promising Alternative ◽  
Randomized Controlled Studies ◽  
Facial Burns ◽  
Aesthetic Results ◽  
Acne Scarring ◽  
Meta Analyses ◽  
Aging Skin

As a promising alternative to traditional treatment, platelet-rich plasma (PRP) is being used to encourage hair growth through the release of growth factors and cytokines. In addition to hair restoration, PRP’s multifactorial capabilities can also be used to treat aging skin, facial scarring, and acne. The purpose of this review is to critically examine the success of PRP in the field of dermatology, with specific attention to the role of PRP in hair restoration. Where possible, meta-analyses were used to evaluate the efficacy of PRP. In androgenetic alopecia (AGA) patients, 3 monthly PRP injections (1 session administered every month for 3 months) exhibited greater efficacy over placebo as measured by change in total hair density (hair/cm2) over the treatment period (mean difference: 25.61, 95% CI: 4.45 to 46.77; P = .02). The studies included in the meta-analysis used a half-head design, which may have influenced the results because of the effects PRP can induce. Controlled studies suggest that 2 to 4 sessions of PRP combined with traditional therapies and procedures can help minimize acne scarring and facial burns, improve aesthetic results, and decrease recovery time. However, data for these indications are lacking and are less robust in design. In conclusion, to achieve an improvement in hair restoration in patients with mild AGA, 3 initial monthly PRP injections should be given. Only upon completion of rigorous, randomized, controlled studies can standardized and effective PRP protocols for treating dermatology conditions such as acne scarring, facial burns, and aging skin be determined.

scholarly journals Platelet-Rich Plasma and Bone Marrow-Derived Mesenchymal Stromal Cells Prevent TGF-β1-Induced Myofibroblast Generation but Are Not Synergistic when Combined: Morphological in vitro Analysis

2018 ◽  
Vol 206 (6) ◽  
pp. 283-295 ◽  
Author(s):  
Flaminia Chellini ◽  
Alessia Tani ◽  
Larissa Vallone ◽  
Daniele Nosi ◽  
Paola Pavan ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Transforming Growth Factor ◽  
Synergistic Effects ◽  
Platelet Rich Plasma ◽  
Therapeutic Option ◽  
Smooth Muscle Actin ◽  
Combined Treatment ◽  
Biologically Active ◽  
Tgf Β1

The persistence of activated myofibroblasts is a hallmark of fibrosis of many organs. Thus, the modulation of the generation/functionality of these cells may represent a strategical anti-fibrotic therapeutic option. Bone marrow-derived mesenchymal stromal cell (MSC)-based therapy has shown promising clues, but some criticisms still limit the clinical use of these cells, including the need to avoid xenogeneic compound contamination for ex vivo cell amplification and the identification of appropriate growth factors acting as a pre-conditioning agent and/or cell delivery vehicle during transplantation, thus enabling the improvement of cell survival in the host tissue microenvironment. Many studies have demonstrated the ability of platelet-rich plasma (PRP), a source of many biologically active molecules, to positively influence MSC proliferation, survival, and functionality, as well as its anti-fibrotic potential. Here we investigated the effects of PRP, murine and human bone marrow-derived MSCs, and of the combined treatment PRP/MSCs on in vitro differentiation of murine NIH/3T3 and human HDFα fibroblasts to myofibroblasts induced by transforming growth factor (TGF)-β1, a well-known pro-fibrotic agent. The myofibroblastic phenotype was evaluated morphologically (cell shape and actin cytoskeleton assembly) and immunocytochemically (vinculin-rich focal adhesion clustering, α-smooth muscle actin and type-1 collagen expression). We found that PRP and MSCs, both as single treatments and in combination, were able to prevent the TGF-β1-induced fibroblast-myofibroblast transition. Unexpectedly, the combination PRP/MSCs had no synergistic effects. In conclusion, within the limitations related to an in vitro experimentation, our study may contribute to providing an experimental background for supporting the anti-fibrotic potential of the combination PRP/MSCs which, once translated “from bench to bedside,” could potentially offer advantages over the single treatments.

Sign in / Sign up

Export Citation Format

Share Document